SARA BOHAN: Open Payments
NPI 1932587284 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,928 in 97 payments from 13 companies in 2025. Trend: 2023 $325 · 2024 $400 · 2025 $1,928
Food & beverage: $1,862Education: $66
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 23 | $423 |
| AstraZeneca Pharmaceuticals LP | 14 | $301 |
| GENZYME CORPORATION | 12 | $226 |
| Regeneron Healthcare Solutions, Inc. | 10 | $221 |
| Grifols USA, LLC | 10 | $215 |
| Insmed, Inc. | 8 | $141 |
| Verona Pharma, Inc. | 9 | $140 |
| Viatris Specialty LLC | 4 | $75 |
| SANOFI-AVENTIS U.S. LLC | 1 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $64 |
Products named: DUPIXENT, NUCALA, Prolastin-C Liquid, FASENRA, Ohtuvayre, Arikayce, TRELEGY ELLIPTA, YUPELRI.
Industry payments across IN — which companies pay providers there.
